INBS

Intelligent Bio Solutions Inc. Common Stock (INBS)

Stock · NASDAQ · Health Care

$1.51as of 10/16/2026

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 3, 2026

INBS Included in List of 12 Health Care Stocks Moving After-Market. Intelligent Bio Solutions was highlighted in a Benzinga report listing 12 health care stocks that saw movement during Thursday's after-market session. The stock currently trades near its 52-week low, with an RSI of 31.9 indicating oversold conditions. This inclusion suggests heightened short-term trading activity, though the company remains a high-beta name with significant volatility.

Active signals

Resistance level
$2.27
Industry
Medical/Dental Instruments

What INBS's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.

SignalTimesMedian 20-session returnHigher after 20 sessions
Volume Spike23-14.8%22%
Bollinger Band Breakdown21-18.6%33%
Bollinger Band Breakout20-15.7%25%
200-Day Moving Average TouchActive now4-3.9%50%
Any 20-session window (baseline)-10.8%33%

Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.

About INBS

Intelligent Bio Solutions Inc., a medical technology company, focused on developing and delivering non-invasive testing, and screening solutions in Asia Pacific, the United States, the United Kingdom, and internationally. The company operates intelligent fingerprinting drug screening system, a platform to analyze fingerprint sweat analysis to detect drugs abuse; and biosensor platform. The company was formerly known…

Sector
Health Care
Industry
Medical/Dental Instruments
Employees
59
Website
ibs.inc/

Fundamentals

1-day range
$1.37$1.5
Market cap
$4.76M
P/E (trailing)
—
P/E (forward)
4.11
EPS (trailing)
$-9.66
Dividend yield
—
Beta
4.57
Avg. volume
159.1K
52-week range
$1.35$24.9

How Intelligent Bio Solutions Inc. Common Stock Makes Money

Where the revenue actually goes — FY2025 annual results

market-wall.comTotalRevenue$3.05MSG&A$8.88M (291%)Cost of Revenue$1.81M (59%)INBS

Source: 10-K filed Aug 15, 2025 · via SEC EDGAR / Finnhub

Gross Profit$1.25M(41%)
Operating Income-$10.64M(-349%)

Forecasts

1 analyst ratings

Buy 86%
Hold 14%
Sell 0%
1-year price forecast
High
$12
+694.7%
Median
$12
+694.7%
Low
$12
+694.7%

Intelligent Bio Solutions Inc. Common Stock Competitors

Chosen by industry and closest market cap.

  • INBS
    Intelligent Bio Solutions Inc. Common Stock
    $1.5
    ▲ 4.17%
    Market cap $4.76MP/E —
    $1.35$24.9
  • XAIR
    Beyond Air Inc. Common Stock
    $2.16
    ▼ 2.26%
    Market cap $4.93MP/E —
    $2.31$55.6
  • VVOS
    Vivos Therapeutics Inc. Common Stock
    $0.131
    ▼ 8.39%
    Market cap $4.47MP/E —
    $0.1276$3.28
  • GCTK
    GlucoTrack Inc. Common Stock
    $0.725
    ▼ 12.86%
    Market cap $4.25MP/E 0.07
    $1.77$136.29
  • SNOA
    Sonoma Pharmaceuticals Inc. Common Stock
    $1.12
    ▼ 2.61%
    Market cap $5.99MP/E —
    $0.8501$4.25
  • NXGL
    NexGel Inc Common Stock
    $5.59
    ▲ 7.92%
    Market cap $3.13MP/E —
    $3$57
  • NVNO
    enVVeno Medical Corporation Common Stock
    $7.47
    ▼ 5.74%
    Market cap $6.93MP/E —
    $7.01$30.8

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

Institutional Ownership

March 31, 2026

Total shares held
204.4K
Total value held
$683.7K
Institutional holders
8
Top holders this quarter
  • Unknown130.0K
  • Unknown38.0K
  • Unknown28.6K
  • Unknown5.8K
  • Unknown1.3K
  • Unknown372
  • Unknown200
  • Unknown200

See the full, filterable feed with live charts on the MarketWall dashboard.

We use analytics to understand how market-wall is used. No personal data is sold.